Related Experiment Video
Updated: May 10, 2026
07:48
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
Improving bladder cancer patient care: a pharmacoeconomic perspective
1Department of Urology, University of Washington, Seattle, WA, USA. jlgore@u.washington.edu
Expert Review of Anticancer Therapy
|June 19, 2013
Summary
Bladder cancer treatment is the most expensive in the US, with high costs for diagnosis and care not always ensuring quality. This review examines spending and quality, seeking improvements for better patient value.
Area of Science:
- Oncology
- Healthcare Economics
- Public Health
Background:
- Bladder cancer treatment incurs the highest per capita cost within the US healthcare system.
- Significant expenditures are linked to diagnosis, management, and surveillance of bladder cancer.
- Current high costs do not consistently correlate with high-quality patient care.
Purpose of the Study:
- To review the primary sources of expenditure in bladder cancer care.
- To analyze population-level data on the quality of bladder cancer care in the USA.
- To identify opportunities for quality improvement to enhance value for bladder cancer patients.
Main Methods:
- Literature review of bladder cancer care expenditures.
- Analysis of population-level studies on bladder cancer care quality in the US.
- Discussion of strategies for improving value in bladder cancer management.
Main Results:
- Detailed examination of cost drivers in bladder cancer diagnosis, treatment, and surveillance.
- Assessment of current quality metrics and patient outcomes in US bladder cancer care.
- Identification of key areas for intervention to improve care efficiency and effectiveness.
Conclusions:
- High costs in bladder cancer care necessitate a focus on value and quality.
- Systematic review and targeted improvements can optimize resource allocation.
- Enhancing care quality offers potential for greater value for patients diagnosed with bladder cancer.
Related Concept Videos
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
01:17Urinary Tract Infection IV: Nursing Management
In managing urinary tract infections (UTIs) in nursing, a comprehensive assessment is essential. Begin by gathering subjective data, such as the patient’s complaints of dysuria (painful urination), urinary frequency, urgency, suprapubic pain, and any lower abdominal discomfort. This information can be complemented by questions regarding previous UTIs, sexual activity, and personal hygiene practices, which can provide insight into risk factors. Objective assessment should focus on signs like...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:22Bioavailability: Influencing Factors
Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...